{"id":28075,"date":"2024-02-19T06:51:20","date_gmt":"2024-02-19T06:51:20","guid":{"rendered":"https:\/\/edukemy.com\/blog\/?p=28075"},"modified":"2024-02-19T06:51:22","modified_gmt":"2024-02-19T06:51:22","slug":"bring-out-the-circumstances-in-2005-which-forced-amendment-to-section-3d-in-the-indian-patent-law-1970-discuss-how-it-has-been-utilized-by-the-supreme-court-in-its-judgment-rejecting-novartis-pate","status":"publish","type":"post","link":"https:\/\/edukemy.com\/blog\/bring-out-the-circumstances-in-2005-which-forced-amendment-to-section-3d-in-the-indian-patent-law-1970-discuss-how-it-has-been-utilized-by-the-supreme-court-in-its-judgment-rejecting-novartis-pate\/","title":{"rendered":"Bring out the circumstances in 2005 which forced amendment to section 3(d) in the Indian Patent Law, 1970. Discuss how it has been utilized by the Supreme court in its judgment rejecting Novartis patent application for \u201cGlivec \u201c. Discuss briefly the pros and cons of the decision. (250 Words, 15 Marks)"},"content":{"rendered":"
\n
\"\"<\/a><\/figure><\/div>\n\n\n

In 2005, significant circumstances prompted the amendment to Section 3(d) of the Indian Patent Law, 1970. This provision was introduced to address concerns regarding evergreening, a practice where pharmaceutical companies extend patent protection by making minor modifications to existing drugs. The amendment aimed to ensure that patents were granted only for genuine innovations rather than trivial modifications. This became particularly relevant in the case of Novartis’ patent application for “Glivec,” a cancer drug. The Supreme Court of India utilized Section 3(d) in its landmark judgment to reject Novartis’ patent application, citing that Glivec did not demonstrate enhanced efficacy over existing formulations, merely involving a modification in the salt form. The court’s decision was lauded for upholding the intent of the law to promote access to affordable medicines by preventing the monopolization of essential drugs. It set a precedent that prioritized public health over pharmaceutical profits and encouraged innovation in genuinely beneficial drugs. However, the decision also sparked debate over its potential impact on research and development investments. Critics argued that stringent patent laws might discourage pharmaceutical companies from investing in developing new drugs, fearing that their innovations could be easily replicated or rejected under similar circumstances. Balancing the interests of innovation, public health, and accessibility remains a challenge, and the Glivec case serves as a pivotal example in navigating these complex dynamics within the framework of patent law in India.<\/p>\n\n\n\n

Tag: <\/strong>Issues relating to intellectual property rights.\u00a0\u00a0<\/p><\/blockquote>\n\n\n\n

\n